Title

PROGNOSIS, DIALYSIS AND TRANSPLANTATION IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY: EVIDENCE FROM REAL-WORLD DATA

Authors/affiliations

Dario Roccatello¹, Michel Kroes², Serge Smeets², Aneesh Thomas George³, Luis Prieto², Jonathan de Courcy⁴, Jade Garratt-Wheeldon⁴, Li Yao⁵

Affiliations: ¹University of Turin, Turin, Italy; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Healthcare Private Limited, Hyderabad, India; ⁴Adelphi Real World, Bollington, England, United Kingdom; ⁵The First Hospital of China Medical University, Shenyang, PR China

Introduction

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, with an estimated annual incidence of 25 per million. Approximately 50% of IgAN patients with proteinuria ≥ 1 g/day progress to kidney failure in 15 years. This analysis aimed to describe prognosis, dialysis and transplantation in IgAN patients.

Methods

The Adelphi IgAN Disease Specific Programme was a non-interventional, retrospective, point-in-time survey of IgAN-treating nephrologists in the US, EU5 (France, Germany, Italy, Spain, UK) and Asia (China and Japan) between June and October 2021. Nephrologists completed structured online records for successive patients presenting with IgAN, including patient's demographics, clinical characteristics and details on dialysis and kidney transplantation (KT).

Results

A total of 295 nephrologists completed records for 1727 patients. The mean patient age was 43.2 years and 59% were men.

The deterioration of kidney function over a median of 95 weeks was evident from the higher proportion of patients in chronic kidney disease (CKD) stages 3b, 4 and 5, at the point of survey compared to at diagnosis. The proportion of patients in CKD stages 3b and 4 increased from 11% to 12% and 6% to 7% respectively from the time of diagnosis to the time of survey. The proportion of patents in CKD stage 5 (kidney failure) also increased from 3% at diagnosis to 5% at the time of survey (**Figure 1**). According to nephrologists, 51% of 1503 patients are expected to progress to kidney failure during their lifetime, of which 13% are expected to progress within three years, thus requiring dialysis or KT. At the time of survey, only 4% of 1727 patients were on dialysis, which included 2% from those with mild/moderate disease and 14% from those with severe disease as per physician perceived severity at diagnosis. Approximately half-of the patients (46%) were expected to require dialysis at some point in the future (40% of those with mild/moderate disease and 80% of those with severe disease). Only 1% of 1727 patients had undergone KT at the time of survey, of which nearly half of the patients had mild/moderate severity (10/21) and slightly more than half of the patients had severe disease (11/21) at diagnosis. Of the remaining patients, 18% were considered eligible for KT (14% from the mild/moderate group and 37% from the severe group). Of the patients deemed eligible for KT, nearly one fourth were on a waiting list (**Table 1**).

Conclusion

The proportion of patients who had CKD stage 3b, stage 4 and kidney failure increased from the time of diagnosis to the time of survey indicating the deterioration of kidney function with time. Although few patients were on dialysis or had received a transplant at the time of the survey, approximately half of the patients were expected to need dialysis in their lifetime and nearly one fourth of patients deemed eligible for a transplant were on a waiting list to undergo transplantation as per nephrologists. There should be an urgency for patients and nephrologists to seek early diagnosis and treatment to slow progression and prevent or delay dialysis. Also, there should be a strong need for more donors to shorten transplantation time and maintain quality of life for longer.

Mild or moderate Total Severe Mean (SD) n (%) Mean (SD) n (%) n (%) Ν Ν Ν Mean (SD) 1727 43.2 (14.91) 1441 42.6 (14.65) 286 46.6 (15.75) Patient age (years) -1727 1016 (59%) 1441 833 (58%) 286 183 (64%) Male patients ---Based on condition at time of survey, when will patients progress to kidney failure 23 (10%) Within next 12 months 1503 41 (3%) 1271 18 (1%) 232 --232 >12months – 3 years 1503 151 (10%) 1271 91 (7%) 60 (26%) ---1503 1271 232 >3 years 568 (38%) 457 (36%) 111 (48%) ---I don't think they will progress to kidney failure 1503 743 (49%) 1271 232 38 (16%) 705 (55%) _ _ -(according to nephrologists) Dialysis Currently receiving dialysis 1727 67 (4%) 1441 28 (2%) 286 39 (14%) _ --As per current condition, when will the patient require chronic dialysis Within next <12 months 1517 33 (2%) 1290 17 (1%) 227 16 (7%) --1517 89 (7%) 12 months – 3 years 154 (10%) 1290 227 65 (29%) --->3 years 1517 510 (34%) 1290 410 (32%) 227 100 (44%) _ --I don't think they will require dialysis 1517 820 (54%) 1290 774 (60%) 227 46 (20%) _ _ -(according to nephrologists) **Kidney transplantation (KT)** 21 (1%) 10 (1%) 1727 Undergone a KT -1441 -286 -11 (4%) Eligible for a KT as per 1706 275 303 (18%) 200 (14%) 103 (37%) -1431 -current condition Currently on waiting list for 303 72 (24%) 200 33 (16%) 103 39 (38%) -_ a KT

Table 1: Prognosis, dialysis and transplantation in IgAN patients, per severity as perceived by physician at diagnosis

Abbreviations: KT: Kidney Transplantation; SD: Standard Deviation




Figure 1: Proportion of patients present in various chronic kidney disease stages at different time points